Mirum Pharmaceuticals (MIRM) Common Equity (2018 - 2026)

Mirum Pharmaceuticals' Common Equity history runs 9 years deep, the most recent figure standing at $242.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 3.96% year-over-year to $242.5 million; the TTM figure through Mar 2026 stood at $242.5 million (up 3.96% YoY), while the FY2025 annual figure was $314.7 million, up 39.47% from the prior year.
• Common Equity was $242.5 million for Q1 2026 at Mirum Pharmaceuticals, down from $314.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $314.7 million in Q4 2025 to a low of $78.6 million in Q2 2023.
• Historically, Common Equity has averaged $207.5 million across 5 years, with a median of $232.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity surged 200.19% in 2022, then slipped 28.98% in 2023.
• A 5-year view of Common Equity shows it stood at $142.0 million in 2022, then jumped by 75.07% to $248.7 million in 2023, then fell by 9.26% to $225.6 million in 2024, then jumped by 39.47% to $314.7 million in 2025, then retreated by 22.94% to $242.5 million in 2026.
• The last three Common Equity figures came in at $242.5 million (Q1 2026), $314.7 million (Q4 2025), and $292.0 million (Q3 2025), per Business Quant data.